Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 10/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 0.77 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.70 |
| ▸ | BLM | P54132 | 2/20 | 0.68 |
| ▸ | MAPT | P10636 | 4/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 1/20 | 0.67 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.67 |
| ▸ | PRKACA | P17612 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.65 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | PSMD14 | O00487 | 1/20 | 0.63 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.63 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4743979 | 0.93 | ROCK1 (0.87) | ROCK1LMNAROCK2MAPTSMN1; SMN2 | |
| SCHEMBL10809273 | 0.87 | LMNA (0.82) | ROCK1LMNAROCK2MAPTSMN1; SMN2 | |
| SCHEMBL2554855 | 0.86 | ROCK1 (1.00) | ROCK1LMNAROCK2BLMMAPT | |
| SCHEMBL24232977 | 0.86 | ROCK1 (0.76) | ROCK1LMNAROCK2BLMMAPT | |
| SCHEMBL10812413 | 0.85 | ROCK1 (0.92) | ROCK1LMNAROCK2BLMMAPT | |
| SCHEMBL2557279 | 0.83 | ROCK1 (1.00) | ROCK1ROCK2PRKACA | |
| SCHEMBL2560360 | 0.83 | ROCK1 (1.00) | ROCK1LMNAROCK2BLMMAPT | |
| SCHEMBL1889024 | 0.80 | MAPT (1.00) | ROCK1LMNAMAPTSMN1; SMN2NPC1 | |
| SCHEMBL22125274 | 0.80 | ROCK1 (0.66) | ROCK1LMNAROCK2BLMMAPT | |
| SCHEMBL2557059 | 0.80 | ROCK1 (1.00) | ROCK1LMNAROCK2MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221808-B2 | Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinase (ROCK) and methods of use | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2013-03-07 | — | — | US | disclosed |
| WO-2011130740-A2 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
| WO-2011130740-A2 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC. (US) | 2011-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059839-A1 | PYRIDYLTHIAZOLE-BASED UREAS AS INHIBITORS OF RHO ASSOCIATED PROTEIN KINASE (ROCK) AND METHODS OF USE | ROCK1, ROCK2, CIT | ROCK1 1/4885LMNA 2437/4885ROCK2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.